Search Result

Search Result

Results for "

ABCB1

" in MCE Product Catalog:

By Targets:	BCRP (2) c-Kit (1) EGFR (1) Fluorescent Dye (1) MDM-2/p53 (1) Monocarboxylate Transporter (1) P-glycoprotein (9) PDGFR (1)
By Research Areas:	Cancer (13)

14

Inhibitors & Agonists

1

Natural
Products

1

Antibodies

Cat. No.	Product Name	Target	Research Areas

BODIPY FL Verapamil hydrochloride	Fluorescent Dye	Others
BODIPY FL Verapamil hydrochloride is a fluorescent dye, it can be used as a molecular probe to label tissues and cells. BODIPY FL Verapamil hydrochloride is a substrate for both ABCB1 and ABCC1.

TTT-28	P-glycoprotein	Cancer
TTT-28 is a synthesized thiazole-valine peptidomimetic, a novel selective inhibitor of ABCB1 (P-gp/MDR1) with high efficacy and low toxicity, which reverses the ATP-binding cassette sub-family B member 1 (ABCB1)-mediated multidrug resistance (MDR) by selectively blocking the efflux function of ABCB1.

WS-898	P-glycoprotein	Cancer
WS-898 is a highly effective *ABCB1* inhibitor capable of reversing paclitaxel (PTX) resistance in drug-resistant SW620/Ad300, KB-C2, and HEK293/ABCB1 cells (IC₅₀ = 5.0, 3.67, and 3.68 nM, respectively).

P-gp inhibitor 5	P-glycoprotein	Cancer
P-gp inhibitor 5 is a potent P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 5 has antiproliferative activity against certain cancer cell lines. P-gp inhibitor 5 is effective in reversing the multidrug resistance (MDR) phenotype in ABCB1/Flp-In TM-293 and KBvin cells by restoring their sensitivity to Vincristine (HY-N0488A) and Paclitaxel (HY-B0015).

MCT1-IN-3	Monocarboxylate Transporter P-glycoprotein	Cancer
MCT1-IN-3 is a monocarboxylate transporter 1 (MCT1) inhibitor with an IC₅₀ value of 81.0 nM. MCT1-IN-3 has also significant inhibitivity against the multidrug transporter *ABCB1. MCT1-IN-3 can be used for the research of cancer.*

Dofequidar fumarate MS-209	P-glycoprotein	Cancer
Dofequidar fumarate(MS-209 fumarate), an orally active quinoline compound, has been reported to overcome MDR by inhibiting ABCB1/P-gp, ABCC1/MDR-associated protein 1, or both.

Ganoderenic acid B	P-glycoprotein	Cancer
Ganoderenic acid B is a lanostane-type triterpene isolated from Ganoderma lucidum. Ganoderenic acid B exhibits potent reversal effect on ABCB1-mediated multidrug resistance of HepG2/ADM cells to Doxorubicin.

GW583340 dihydrochloride	EGFR	Cancer
GW 583340 dihydrochloride is a potent dual EGFR/ErbB2 tyrosine kinase inhibitor (IC₅₀: 0.01 and 0.014 μM respectively). GW 583340 dihydrochloride reverses ABCG2- and ABCB1-mediated drug resistance. GW 583340 dihydrochloride has anti-cancer activity.

MC70	P-glycoprotein	Cancer
MC70 is a potent and non-selective P-glycoprotein (P-gp) inhibitor with an EC₅₀ of 0.69 µM. MC70 is an ABC transporters inhibitor and anticancer agent. MC70 interacts with ABCB1, ABCG2 and ABCC1.

ML230 CID44640177; SID 88095709	BCRP	Cancer
ML230 (CID44640177; SID 88095709) is a selective inhibitor of ATP-binding cassette (ABC) transporter ABCG2, and 36-fold selective for ABCG2 over ABCB1 with EC₅₀s values of 0.13 μM and 4.65 μM, respectively.

Efflux inhibitor-1	BCRP	Cancer
Efflux inhibitor-1 (compound 2) is a pyrazolo[1,5-a]pyrimidine efflux inhibitor. Efflux inhibitor-1 selectively targets toward ABCG2/BCRP over *ABCB1* with IC₅₀s of 0.45 μM and 2.17 μM, respectively.

Anticancer agent 50	MDM-2/p53 P-glycoprotein	Cancer
Anticancer agent 50 (compound 6) is a potent ABCB1 efflux pump modulator. Anticancer agent 50 shows cytotoxic effects and antiproliferative effects. Anticancer agent 50 decreases the expression of cyclin D1 and induces p53 expression. Anticancer agent 50 has the potential for the research of T-lymphoma.

Avapritinib BLU-285	c-Kit PDGFR	Cancer
Avapritinib (BLU-285) is a highly potent, selective, and orally active KIT and PDGFRA activation loop mutant kinases inhibitor with IC₅₀s of 0.27 and 0.24 nM for KIT D816V and PDGFRA D842V, respectively. Avapritinib (BLU-285) binds the active conformation of the kinase and shows antitumor activity. Avapritinib (BLU-285) attenuates the transport function of both ABCB1 and ABCG2.

YS-370	P-glycoprotein	Cancer
YS-370 (compound 44) is a potent, high selective, and orally active inhibitor of P-glycoprotein (P-gp). YS-370 stimulates the P-gp ATPase activity and has moderate inhibition against CYP3A4. YS-370 effectively reverses multidrug resistance (MDR) to paclitaxel and colchicine in SW620/AD300 and HEK293T-ABCB1 cells. YS-370 in combination with paclitaxel achieves much stronger antitumor activity.

MCE Magic Cece

MedChemExpress: Contact Us; About Us; Headquarters; Distributors; Statement on False Report; Careers

Customer Support: Technical Support; Service; Ordering Information; Easy Return; Shipping Rates & Policies; Intellectual Property Promise

Resources: Free Sample; Resources; Molarity Calculator; Dilution Calculator; Terms & Conditions; Reconstitution Calculator; Specific Activity Calculator

Subscribe to our E-newsletter

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

Copyright © 2013-2023 MedChemExpress. All Rights Reserved.: Site Map Privacy Policy

Join with us